Compare · CDXS vs IFF
CDXS vs IFF
Side-by-side comparison of Codexis Inc. (CDXS) and International Flavors & Fragrances Inc. (IFF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDXS and IFF operate in Major Chemicals (Industrials), so they compete in similar markets.
- IFF is the larger of the two at $23.04B, about 154.7x CDXS ($148.9M).
- Both names hit the wire about 3 times in the past 4 weeks.
- IFF has more recent analyst coverage (25 ratings vs 12 for CDXS).
- Company
- Codexis Inc.
- International Flavors & Fragrances Inc.
- Price
- -
- -
- Market cap
- $148.9M
- $23.04B
- 1M return
- -
- +6.80%
- 1Y return
- -
- +42.21%
- Industry
- Major Chemicals
- Major Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- News (4w)
- 3
- 3
- Recent ratings
- 12
- 25
Codexis Inc.
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
International Flavors & Fragrances Inc.
International Flavors & Fragrances Inc., together with its subsidiaries, manufactures and sells cosmetic active and natural health ingredients for use in various consumer products in Europe, Africa, the Middle East, Greater Asia, North America, and Latin America. It operates through four segments: Nourish, Scent, Health & Biosciences, and Pharma Solutions. The Nourish segment offers flavor compounds; savory solutions, such as marinades or powder blends of flavors, natural colors, seasonings, functional ingredients, and natural anti-oxidants; and inclusions. It also provides nutrition and specialty ingredients primarily consist of natural health ingredients, natural food protection products, and natural colors and flavor ingredients. The Scent segment provides fragrance compounds, which include fine fragrances comprising perfumes and colognes, as well as consumer fragrances; fragrance ingredients comprising synthetic and natural ingredients that could be combined with other materials to create fragrance and consumer compounds; and cosmetic active ingredients consisting of active and functional ingredients, botanicals, and delivery systems to support its customers' cosmetic and personal care product lines. The Health & Biosciences segment develops and produces enzymes, food cultures, probiotics, and specialty ingredients. The Pharma Solutions segment produces and sells cellulosics and alginates-based pharma excipients. The company sells its products primarily to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, dietary supplements, infant and elderly nutrition, functional food, and pharmaceutical and oral care products. International Flavors & Fragrances Inc. was founded in 1833 and is headquartered in New York, New York.
Latest CDXS
- SEC Form 4 filed by Codexis Inc.
- SEC Form 4 filed by Codexis Inc.
- Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
- Codexis to Participate in Cantor Global Healthcare Conference 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Codexis Inc.
- SEC Form 10-Q filed by Codexis Inc.
- Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Codexis Reports Second Quarter 2026 Financial Results
- Codexis Appoints David Butler, PhD, to Strategic Advisory Board
- Codexis to Report Second Quarter 2026 Financial Results on August 11
Latest IFF
- IFF to Release Third Quarter 2026 Results on November 3, 2026
- IFF Identifies the Life-Stage Insights Shaping Dairy’s Future
- IFF Introduces AQUASCENT™: Advanced Water-Based Fragrance Technology
- IFF Launches Omni-Bos™ PHY to Help Dairy Producers Get More Value from Feed
- KeyBanc Capital Markets initiated coverage on Intl Flavors
- IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers
- President, Scent Teles De Mendonca Ana Paula sold $475,692 worth of shares (5,718 units at $83.19), closing all direct ownership in the company (SEC Form 4)
- IFF to Webcast Fireside Chat at Barclays Global Consumer Conference on Sept. 10
- Controller & CAO Birenkrant Marc sold $85,000 worth of shares (1,000 units at $85.00), decreasing direct ownership by 22% to 3,446 units (SEC Form 4)
- EVP, CFO Deveau Michael sold $754,970 worth of shares (8,825 units at $85.55), decreasing direct ownership by 63% to 5,199 units (SEC Form 4)